CD274 and breast cancer: Besides programmed death ligand-1 (PD-L1) expression, tumour-infiltrating lymphocytes (TILs), microsatellite instability (MMRd), and high tumour mutation burden (TMB), additional biomarkers for BC immunotherapy are still a significant unmet medical need (5–7).